METHOD FOR ANALYZING PHYTOCHEMICALS TARGETING CHROMOSOME REGION MAINTENANCE 1 (CRM1) FOR CERVICAL CANCER TREATMENT

Abstract

ABSTRACT A method (100) for analyzing phytochemicals targeting CRM1 for cervical cancer treatment, comprising: identifying a library of phytochemicals derived from plant sources; utilizing computational models to predict the interaction between phytochemicals and CRM1; conducting in vitro assays to evaluate the inhibitory effects of phytochemicals on CRM1 activity; analyzing cellular models to assess the impact of phytochemicals on CRM1-mediated nuclear export. <>

Specification

Description:FIELD OF THE DISCLOSURE
[0001] This invention generally relates to a field of molecular biology and cancer treatment, specifically to a method for analyzing phytochemicals that target Chromosome Region Maintenance 1 (CRM1) for the treatment of cervical cancer. The invention aims to identify potential phytochemical compounds that can modulate CRM1 activity, providing a novel therapeutic approach for cervical cancer treatment.
BACKGROUND

[0002] The subject matter discussed in the background section should not be assumed to be prior art merely as a result of its mention in the background section. Similarly, a problem mentioned in the background section or associated with the subject matter of the background section should not be assumed to have been previously recognized in the prior art. The subject matter in the background section merely represents different approaches, which in and of themselves may also correspond to implementations of the claimed technology.
[0003] Cervical cancer, one of the leading ca , Claims:1. A method (100) for analyzing phytochemicals targeting CRM1 for cervical cancer treatment, comprising:
identifying a library of phytochemicals derived from plant sources;
utilizing computational models to predict the interaction between phytochemicals and CRM1;
conducting in vitro assays to evaluate the inhibitory effects of phytochemicals on CRM1 activity;
analyzing cellular models to assess the impact of phytochemicals on CRM1-mediated nuclear export.

2. The method (100) as claimed in claim 1, wherein the computational models include molecular docking and molecular dynamics simulations.

3. The method (100) as claimed in claim 1, wherein the in vitro assays include enzyme-linked immunosorbent assays (ELISA) and Western blotting.

4. The method (100) as claimed in claim 1, wherein the cellular models are cervical cancer cell lines.

Documents